Press Release: Stratatech : Mallinckrodt's Stratatech Company Awarded $26 Million in Additional BARDA Funding for Pediatric Studies of StrataGraft® Skin Tissue in Thermal Burns
STAINES-UPON-THAMES, United Kingdom, Oct. 15, 2018 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today announced that Stratatech, a Mallinckrodt company, was awarded approximately $26 million in additional Project BioShield funding by the ...
Read full article »
Stratatech is a regenerative medicine company that focuses on the development of novel skin substitute products for therapeutic and research uses.
Read more